184,835 Shares in Becton, Dickinson and Company $BDX Bought by Danske Bank A S

Danske Bank A S purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 184,835 shares of the medical instruments supplier’s stock, valued at approximately $34,596,000. Danske Bank A S owned 0.06% of Becton, Dickinson and Company as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. SOA Wealth Advisors LLC. lifted its position in Becton, Dickinson and Company by 256.8% in the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the period. Activest Wealth Management lifted its holdings in shares of Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 97 shares during the period. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter valued at about $25,000. Cornerstone Planning Group LLC boosted its position in shares of Becton, Dickinson and Company by 463.3% during the 3rd quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 139 shares in the last quarter. Finally, Accredited Wealth Management LLC increased its stake in Becton, Dickinson and Company by 77.8% in the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 70 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $158.02 on Thursday. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The firm has a market cap of $44.99 billion, a PE ratio of 25.78, a price-to-earnings-growth ratio of 11.72 and a beta of 0.24. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The company’s 50-day moving average price is $187.47 and its two-hundred day moving average price is $189.31.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.15 billion. During the same quarter last year, the business posted $3.43 earnings per share. The company’s revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 68.52%.

Becton, Dickinson and Company announced that its board has authorized a stock repurchase plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of brokerages have commented on BDX. Zacks Research cut shares of Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 11th. Stifel Nicolaus upped their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. JPMorgan Chase & Co. cut their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Barclays initiated coverage on Becton, Dickinson and Company in a research note on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 price target on the stock. Finally, Bank of America upped their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research report on Monday, January 5th. Five investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $195.46.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the transaction, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 2,787 shares of company stock valued at $551,391. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.